Cargando…

Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19

Mostrar otras versiones (1)

BACKGROUND: Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arvanitis, Panos, Lerner, Alexis Hope, Vieira, Kendra, Almaghlouth, Nouf, Farmakiotis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882636/ https://www.ncbi.nlm.nih.gov/pubmed/36711556 http://dx.doi.org/10.21203/rs.3.rs-2433445/v1

Ejemplares similares

Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023)

mRNA Vaccination Decreases COVID-19-Associated Morbidity and Mortality Among Organ Transplant Recipients: A Contemporary Cohort Study
por: Lerner, Alexis Hope, et al.
Publicado: (2022)

631. Using a commercially available assay that measures cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity to predict protection against CMV: Results from a prospective, blinded clinical trial
por: Almaghlouth, Nouf K, et al.
Publicado: (2023)

39. Anti-Spike Monoclonal Antibody Therapy for Kidney Transplant Recipients with COVID-19
por: Hardesty, Anna, et al.
Publicado: (2021)

508. Nirmatrelvir/ritonavir use among patients with cancer and COVID-19 is associated with improved clinical outcomes: Single-institution case-control study
por: Arvanitis, Panos, et al.
Publicado: (2023)

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
por: Guermazi, Dorra, et al.
Publicado: (2023)

Refractory Bilateral Tubo-Ovarian Abscesses in a Patient with Iatrogenic Hypogammaglobulinemia
por: Klein, Elizabeth J., et al.
Publicado: (2023)

Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature
por: Apostolopoulou, Anna, et al.
Publicado: (2020)

191. The impact of antibiotic use on clinical outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Vafea, Maria Tsikala, et al.
Publicado: (2020)

A kidney transplant recipient with nausea, vomiting, and diarrhea after a recent COVID-19 exposure
por: Lerner, Alexis H., et al.
Publicado: (2020)

Decreased Renal Accumulation of Biotinylated Chimeric Monoclonal Antibody‐Neocarzinostatin Conjugate after Administration of Avidin
por: Otsuji, Eigo, et al.
Publicado: (1997)

Delivering Monoclonal Antibody Infusions to Novel Outpatient Settings
por: Minnich, Amy, et al.
Publicado: (2022)

512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?
por: SanFilippo, Savanna, et al.
Publicado: (2021)

A multimodal strategy to improve race/ethnic group equity in administration of neutralizing monoclonal antibody treatment for COVID-19 outpatients
por: Fish, Lindsey E., et al.
Publicado: (2023)

Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
por: Goo, Junghyun, et al.
Publicado: (2020)

Administration of Monoclonal Antibody for COVID-19 in Patient Homes
por: Malani, Anurag N., et al.
Publicado: (2021)

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
por: Rogers, Ralph, et al.
Publicado: (2020)

Correction to: Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
por: Rogers, Ralph, et al.
Publicado: (2020)

Comparison of COVID-19 outcomes in organ transplant recipients (OTr) and non-transplant patients: a study protocol for rapid review
por: Lerner, Alexis H., et al.
Publicado: (2021)

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
por: Bussing, David, et al.
Publicado: (2021)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
por: Piepenbrink, Michael S., et al.
Publicado: (2022)

Pregnancy outcomes after administration of monoclonal antibody therapy for COVID-19
por: Martinez-Baladejo, Maria T., et al.
Publicado: (2023)

Mechanically interlocked functionalization of monoclonal antibodies
por: Bzymek, Krzysztof P., et al.
Publicado: (2018)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

ALCOHOLISM AMONG OUTPATIENTS WITH PSYCHIATRIC MORBIDITY
por: Dhadphale, Manohar
Publicado: (1997)

Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein
por: Bordoloi, Devivasha, et al.
Publicado: (2021)

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
por: Liu, Zhuoming, et al.
Publicado: (2021)

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies
por: Adedeji, Adeyemi O., et al.
Publicado: (2022)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Outpatient Management of COVID-19 With Monoclonal Antibody Therapy in a Young Renal Transplant Patient
por: Malik, Bilal, et al.
Publicado: (2021)

Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients
por: Wynia, Matthew K., et al.
Publicado: (2023)

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19
por: Ruggeri, Matteo, et al.
Publicado: (2023)

Cellular distribution of monoclonal antibody in human tumours after i.v. administration.
por: Moshakis, V., et al.
Publicado: (1981)

Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis
por: Guidotti, Elisa, et al.
Publicado: (2022)

Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era
por: Farmakiotis, Dimitrios, et al.
Publicado: (2020)

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
por: Wang, Chunyan, et al.
Publicado: (2021)

Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA
por: Fukushi, Shuetsu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bguk9a6mucpoko7v886pnddp23